

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

1. (Canceled)
2. (Canceled)
3. (Currently Amended) A method of treating or preventing a bacterial infection by pathogenic *Mycoplasma* bacteria comprising the step of administering an antibacterially effective amount of a composition comprising a gemifloxacin compound, or an antibacterially effective derivative thereof, to a mammal suspected of having or being at risk of having an infection with pathogenic *Mycoplasma* bacteria.
4. – 7. (Canceled)
8. (Original) The method of claim 3 wherein said mammal is a human.
9. – 11. (Canceled)
12. (New) The method of claim 3 wherein said pathogenic *Mycoplasma* bacteria is a member of the genus *Mycoplasma*.
13. (New) The method of claim 12 wherein said bacteria is selected from the group consisting of *Mycoplasma hominis* and *Mycoplasma fermentans*.
14. (New) The method of claim 12 wherein said bacteria is selected from the group consisting of *Mycoplasma pneumoniae*, *Mycoplasma genitalium*, and *Mycoplasma penetrans*.
15. (New) The method of claim 3 wherein said bacteria is a member of the genus *Ureaplasma*.
16. (New) The method of claim 15 wherein said bacteria is *Ureaplasma urealyticum*.

17. (New) The method according to claim 3 wherein the gemifloxacin compound is gemifloxacin or a pharmaceutically acceptable salt thereof.

18. (New) The method according to claim 17 wherein the gemifloxacin compound is gemifloxacin mesylate or a hydrate thereof.

19. (New) The method according to claim 18 wherein the gemifloxacin compound is gemifloxacin mesylate sesquihydrate.

20. (New) The method according to claim 12 wherein the gemifloxacin compound is gemifloxacin or a pharmaceutically acceptable salt thereof.

21. (New) The method according to claim 20 wherein the gemifloxacin compound is gemifloxacin mesylate or a hydrate thereof.

22. (New) The method according to claim 21 wherein the gemifloxacin compound is gemifloxacin mesylate sesquihydrate.

23. (New) The method according to claim 13 wherein the gemifloxacin compound is gemifloxacin or a pharmaceutically acceptable salt thereof.

24. (New) The method according to claim 23 wherein the gemifloxacin compound is gemifloxacin mesylate or a hydrate thereof.

25. (New) The method according to claim 24 wherein the gemifloxacin compound is gemifloxacin mesylate sesquihydrate.

26. (New) The method according to claim 14 wherein the gemifloxacin compound is gemifloxacin or a pharmaceutically acceptable salt thereof.

27. (New) The method according to claim 26 wherein the gemifloxacin compound is gemifloxacin mesylate or a hydrate thereof.

28. (New) The method according to claim 27 wherein the gemifloxacin compound is gemifloxacin mesylate sesquihydrate.

29. (New) The method according to claim 15 wherein the gemifloxacin compound is gemifloxacin or a pharmaceutically acceptable salt thereof.

30. (New) The method according to claim 29 wherein the gemifloxacin compound is gemifloxacin mesylate or a hydrate thereof.

31. (New) The method according to claim 30 wherein the gemifloxacin compound is gemifloxacin mesylate sesquihydrate.

32. (New) The method according to claim 16 wherein the gemifloxacin compound is gemifloxacin or a pharmaceutically acceptable salt thereof.

33. (New) The method according to claim 32 wherein the gemifloxacin compound is gemifloxacin mesylate or a hydrate thereof.

34. (New) The method according to claim 33 wherein the gemifloxacin compound is gemifloxacin mesylate sesquihydrate.